Compare Dollar General Corp. (DG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Inovio Pharmaceuticals Inc — how do they compare? Dollar General Corp. trades at $119.72 (market cap $26.49B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Dollar General Corp. is far larger — about 337.2× Inovio Pharmaceuticals Inc's market cap, and Dollar General Corp. pays a 1.97% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DG | INO | |
|---|---|---|
Market Cap | $26.49B | $78.55M |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $2.87 |
52-Week Low | $95.94 | $0.66 |
Enterprise Value | $40.93B | $49.56M |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $119.40, down 2.44% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, while consistently beating earnings expectations in recent quarters. Revenue growth continues with $40.61B in 2025, though profit margins have compressed from 7.01% in 2022 to 2.77% in 2025. Analyst consensus remains positive with 52% buy ratings and a $128.45 price target, representing 7.6% upside potential.
DG presents a compelling value opportunity with reasonable valuation metrics and consistent earnings beats, though margin compression and competitive pressures pose risks. The stock's current price near support levels combined with positive analyst sentiment suggests potential for recovery, but investors should monitor margin trends and competitive dynamics in the discount retail sector.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
